Study of ZG005 Combined With Bevacizumab Versus Sintilimab Combined With Bevacizumab in Advanced Hepatocellular Carcinoma

This study is comparing two different immunotherapy combinations for treating advanced liver cancer (hepatocellular carcinoma) that cannot be surgically removed. It tests a new drug called ZG005 combined with bevacizumab (a drug that cuts off blood supply to tumors) against sintilimab (an established immunotherapy) combined with bevacizumab. The goal is to see which combination works better and is safer. **You may be eligible if...** - You are between 18 and 75 years old - You have been diagnosed with advanced hepatocellular carcinoma (liver cancer) - You have a good overall health status (ECOG performance score of 0 or 1 — meaning you are fully active or able to carry out light activities) - You are expected to live at least 12 weeks - You have read and fully understood the study and signed the informed consent form **You may NOT be eligible if...** - Your doctor determines for any medical reason that you are not suitable for this study Talk to your doctor to see if this trial is right for you.